Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals (ETON)
:ETON
ETON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.40 - $21.48
Previous CloseN/A
Volume127.06K
Average Volume (3M)538.83K
Market Cap
$395.02M
Enterprise Value$361.72M
Total Cash (Recent Filing)$17.42M
Total Debt (Recent Filing)$30.08M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 12, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding26,817,535
10 Day Avg. Volume318,160
30 Day Avg. Volume538,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue7.48
Enterprise Value/Gross Profit12.80
Enterprise Value/Ebitda-266.95
Forecast
1Y Price Target
$30.50Price Target Upside111.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionExpect a smooth launch due to the management’s strength in commercial execution.
Drug ApprovalET-600, if approved, will be the only FDA-approved oral liquid formulation of desmopressin.
Product LaunchKhindivi could potentially become the hydrocortisone formulation of choice for patients with adrenal insufficiency and gain adoption rapidly among caregivers and physicians.
Revenue GrowthEton Pharmaceuticals has reported 16 sequential quarters of growth, with a 4Q top-line beat and 12% sequential growth.
Bears Say
CompetitionThe company faces competition which is a risk factor for its Buy rating.
Risks And ChallengesRisks to the Buy rating include clinical, commercial, collaboration, dilution, legal and intellectual property, and competition.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $3.40 and its highest was $21.48 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $395.02M.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of $0.023 by -$0.123.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of -$0.1 in its last earnings report, missing expectations of $0.023. Following the earnings report the stock price went up 0.293%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.50 (111.95% Upside)
$30.50 (111.95% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
336.00%
12-Months-Change
Fundamentals
Return on Equity
-22.95%
Trailing 12-Months
Asset Growth
172.88%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Eton Pharmaceuticals demonstrated strong revenue growth and successful product launches, particularly with Increlex and Galzin. However, the company faces challenges with increased operating expenses and a net loss for the quarter. Despite these lowlights, the overall performance and future prospects indicate a positive trend.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$30.50
▲(111.95% Upside)
Technical Analysis
Ownership Overview
24.52% Insiders
5.60% Mutual Funds
1.18% Other Institutional Investors
59.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---